Loading...
Loading...
Adam Feuerstein, senior biotech writer at the TheStreet.com,
tweeted that he thinks that Cell Therapeutics, Inc.
CTIC may buy Sunesis Pharmaceuticals, Inc.
SNSS.
This is all speculation on his part, and there has been no talk of a merger between the companies.
Sunesis Pharmaceuticals, Inc. focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Cell Therapeutics, Inc. develops, acquires, and commercializes oncology products for the treatment of cancer. It is developing pixantrone, a Phase III single-agent clinical trial product for the treatment of non-Hodgkins.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in